Morepen Laboratories (NSE:MOREPENLAB, BOM:500288) secured a multi-year contract development and manufacturing organization (CDMO) mandate worth about 8.25 billion Indian rupees from an undisclosed global pharmaceutical company, according to an Indian bourse filing on Monday.
Shares of the company jumped over 13% in recent trade.
Supplies under the contract are expected to begin within four to five months, with execution planned through the first quarter of the next financial year, subject to operational and regulatory clearances, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments